Ignite Creation Date:
2024-05-06 @ 1:19 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03988036
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2019-03-07
Brief Title:
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype Keyriched-1
Sponsor:
West German Study Group
Organization:
West German Study Group
Organization Data
Organization:
West German Study Group
Class:
OTHER
Study ID:
WSG-AM09
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
West German Study Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |
| NanoString Technologies Inc | INDUSTRY |